PIK3CA mutations in non-small cell lung cancer (NSCLC): Genetic heterogeneity, prognostic impact and incidence of prior malignancies

Oncotarget

Volumn 6, Issue 2, 2015, Pages 1315-1326

  Scheffler, Matthias ^a,b   Bos, Marc ^a,b   Gardizi, Masyar ^a,b   König, Katharina ^a,b   Michels, Sebastian ^a,b   Fassunke, Jana ^a,b   Heydt, Carina ^a,b   Künstlinger, Helen ^a,b   Ihle, Michaela ^a,b   Ueckeroth, Frank ^a,b   Albus, Kerstin ^a,b   Serke, Monika ^c   Gerigk, Ulrich ^d   Schulte, Wolfgang ^d   Töpelt, Karin ^a,b   Nogova, Lucia ^a,b   Zander, Thomas ^a,b   Engel Riedel, Walburga ^b   Stoelben, Erich ^b   Ko, Yon Dschun ^e   Randerath, Winfried ^f   Kaminsky, Britta ^f   Panse, Jens ^g   Becker, Carolin ^g   Hellmich, Martin ^b   Merkelbach Bruse, Sabine ^a,b   Heukamp, Lukas C ^a,b   Büttner, Reinhard ^a,b   Wolf, Jürgen ^a,b   more..

^a University of Cologne   (Germany)

^b UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

^c Dept of Pulmonary Medicine and Thoracic Surgery   (Germany)

^d Malteser Hospital   (Germany)

^e Johanniter Krankenhaus   (Germany)

^f Bethanien Hospital   (Germany)

^g UNIVERSITY HOSPITAL RWTH AACHEN   (Germany)

Author keywords

Lung cancer; Mutation; Non small cell lung cancer; PI3K; PIK3CA

Indexed keywords

ANTINEOPLASTIC AGENT; BEVACIZUMAB; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; PEMETREXED; PLATINUM COMPLEX; PHOSPHATIDYLINOSITOL 3 KINASE; PIK3CA PROTEIN, HUMAN;

ADULT; AGED; ARTICLE; BLADDER CANCER; CANCER CHEMOTHERAPY; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CONTROLLED STUDY; EPIDERMAL GROWTH FACTOR RECEPTOR GENE; EXON; FEMALE; GENE; GENE MUTATION; GENETIC HETEROGENEITY; HUMAN; HUMAN TISSUE; KIDNEY CARCINOMA; LUNG ADENOCARCINOMA; MAJOR CLINICAL STUDY; MALE; METASTASIS; MIDDLE AGED; MULTIPLE CYCLE TREATMENT; NEXT GENERATION SEQUENCING; NON SMALL CELL LUNG CANCER; ONCOGENE; ONCOGENE H RAS; ONCOGENE K RAS; OVERALL SURVIVAL; PIK3CA GENE; POINT MUTATION; SECOND CANCER; SQUAMOUS CELL LUNG CARCINOMA; VERY ELDERLY; ADENOCARCINOMA; CARCINOMA, NON-SMALL-CELL LUNG; CARCINOMA, SQUAMOUS CELL; COHORT ANALYSIS; GENE FREQUENCY; GENETICS; HIGH THROUGHPUT SEQUENCING; LUNG NEOPLASMS; MUTATION; PATHOLOGY; PROCEDURES; PROGNOSIS; SURVIVAL;

ADENOCARCINOMA; AGED; AGED, 80 AND OVER; CARCINOMA, NON-SMALL-CELL LUNG; CARCINOMA, SQUAMOUS CELL; COHORT STUDIES; EXONS; FEMALE; GENE FREQUENCY; GENETIC HETEROGENEITY; HIGH-THROUGHPUT NUCLEOTIDE SEQUENCING; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; MUTATION; NEOPLASMS, SECOND PRIMARY; PHOSPHATIDYLINOSITOL 3-KINASES; PROGNOSIS; SURVIVAL ANALYSIS;

EID: 84921724307     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.2834     Document Type: Article

References (28)

1. Jemal A, Simard EP, Dorell C, Noone AM, Markowitz LE, Kohler B, Eheman C, Saraiya M, Bandi P, Saslow D, Cronin KA, Watson M, Schiffman M, Henley SJ, Schymura MJ, Anderson RN, et al. Annual Report to the Nation on the Status of Cancer, 1975-2009, featuring the burden and trends in human papillomavirus(HPV)-associated cancers and HPV vaccination coverage levels. Journal of the National Cancer Institute. 2013; 105(3):175-201.
2. Mok TS, Wu YL, Thongprasert S, Yang CH, Chu DT, Saijo N, Sunpaweravong P, Han B, Margono B, Ichinose Y, Nishiwaki Y, Ohe Y, Yang JJ, Chewaskulyong B, Jiang H, Duffield EL, et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. The New England Journal of Medicine. 2009; 361(10):947-957.
3. Rosell R, Carcereny E, Gervais R, Vergnenegre A, Massuti B, Felip E, Palmero R, Garcia-Gomez R, Pallares C, Sanchez JM, Porta R, Cobo M, Garrido P, Longo F, Moran T, Insa A, et al. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. The Lancet Oncology. 2012; 13(3):239-246.
4. Kwak EL, Bang YJ, Camidge DR, Shaw AT, Solomon B, Maki RG, Ou SH, Dezube BJ, Janne PA, Costa DB, Varella-Garcia M, Kim WH, Lynch TJ, Fidias P, Stubbs H, Engelman JA, et al. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. The New England Journal of Medicine. 2010; 363(18):1693-1703.
5. Camidge DR, Bang YJ, Kwak EL, Iafrate AJ, Varella-Garcia M, Fox SB, Riely GJ, Solomon B, Ou SH, Kim DW, Salgia R, Fidias P, Engelman JA, Gandhi L, Janne PA, Costa DB, et al. Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study. The Lancet Oncology. 2012; 13(10):1011-1019.
6. Buettner R, Wolf J and Thomas RK. Lessons learned from lung cancer genomics: the emerging concept of individualized diagnostics and treatment. Journal of Clinical Oncology. 2013; 31(15):1858-1865.
7. Oxnard GR, Binder A and Janne PA. New targetable oncogenes in non-small-cell lung cancer. Journal of Clinical Oncology. 2013; 31(8):1097-1104.
8. Engelman JA, Luo J and Cantley LC. The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism. Nat Rev Genet. 2006; 7(8):606-619.
9. Yuan TL and Cantley LC. PI3K pathway alterations in cancer: variations on a theme. Oncogene. 2008; 27(41):5497-5510.
10. Courtney KD, Corcoran RB and Engelman JA. The PI3K pathway as drug target in human cancer. Journal of Clinical Oncology. 2010; 28(6):1075-1083.
11. Samuels Y, Wang Z, Bardelli A, Silliman N, Ptak J, Szabo S, Yan H, Gazdar A, Powell SM, Riggins GJ, Willson JK, Markowitz S, Kinzler KW, Vogelstein B and Velculescu VE. High frequency of mutations of the PIK3CA gene in human cancers. Science. 2004; 304(5670):554.
12. Engelman JA, Chen L, Tan X, Crosby K, Guimaraes AR, Upadhyay R, Maira M, McNamara K, Perera SA, Song Y, Chirieac LR, Kaur R, Lightbown A, Simendinger J, Li T, Padera RF, et al. Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers. Nat Med. 2008; 14(12):1351-1356.
13. Garcia-Echeverria C and Sellers WR. Drug discovery approaches targeting the PI3K/Akt pathway in cancer. Oncogene. 2008; 27(41):5511-5526.
14. Samuels Y and Velculescu VE. Oncogenic mutations of PIK3CA in human cancers. Cell Cycle. 2004; 3(10):1221-1224.
15. Huang CH, Mandelker D, Schmidt-Kittler O, Samuels Y, Velculescu VE, Kinzler KW, Vogelstein B, Gabelli SB and Amzel LM. The structure of a human p110alpha/p85alpha complex elucidates the effects of oncogenic PI3Kalpha mutations. Science. 2007; 318(5857):1744-1748.
16. Kang S, Bader AG and Vogt PK. Phosphatidylinositol 3-kinase mutations identified in human cancer are oncogenic. Proceedings of the National Academy of Sciences of the United States of America. 2005; 102(3):802-807.
17. Kawano O, Sasaki H, Endo K, Suzuki E, Haneda H, Yukiue H, Kobayashi Y, Yano M and Fujii Y. PIK3CA mutation status in Japanese lung cancer patients. Lung Cancer. 2006; 54(2):209-215.
18. Yamamoto H, Shigematsu H, Nomura M, Lockwood WW, Sato M, Okumura N, Soh J, Suzuki M, Wistuba, II, Fong KM, Lee H, Toyooka S, Date H, Lam WL, Minna JD and Gazdar AF. PIK3CA mutations and copy number gains in human lung cancers. Cancer Research. 2008; 68(17):6913-6921.
19. Sun Y, Ren Y, Fang Z, Li C, Fang R, Gao B, Han X, Tian W, Pao W, Chen H and Ji H. Lung adenocarcinoma from East Asian never-smokers is a disease largely defined by targetable oncogenic mutant kinases. Journal of Clinical Oncology. 2010; 28(30):4616-4620.
20. Chaft JE, Arcila ME, Paik PK, Lau C, Riely GJ, Pietanza MC, Zakowski MF, Rusch V, Sima CS, Ladanyi M and Kris MG. Coexistence of PIK3CA and other oncogene mutations in lung adenocarcinoma-rationale for comprehensive mutation profiling. Mol Cancer Ther. 2012; 11(2):485-491.
21. Pao W and Hutchinson KE. Chipping away at the lung cancer genome. Nat Med. 2012; 18(3):349-351.
22. Bendell JC, Rodon J, Burris HA, de Jonge M, Verweij J, Birle D, Demanse D, De Buck SS, Ru QC, Peters M, Goldbrunner M and Baselga J. Phase I, dose-escalation study of BKM120, an oral pan-Class I PI3K inhibitor, in patients with advanced solid tumors. Journal of Clinical Oncology. 2012; 30(3):282-290.
23. Dearden S, Stevens J, Wu YL and Blowers D. Mutation incidence and coincidence in non small-cell lung cancer: meta-analyses by ethnicity and histology (mutMap). Annals of Oncology/ESMO. 2013.
24. Rekhtman N, Paik PK, Arcila ME, Tafe LJ, Oxnard GR, Moreira AL, Travis WD, Zakowski MF, Kris MG and Ladanyi M. Clarifying the spectrum of driver oncogene mutations in biomarker-verified squamous carcinoma of lung: lack of EGFR/KRAS and presence of PIK3CA/AKT1 mutations. Clinical Cancer Research. 2012; 18(4):1167-1176.
25. Sequist LV, Heist RS, Shaw AT, Fidias P, Rosovsky R, Temel JS, Lennes IT, Digumarthy S, Waltman BA, Bast E, Tammireddy S, Morrissey L, Muzikansky A, Goldberg SB, Gainor J, Channick CL, et al. Implementing multiplexed genotyping of non-small-cell lung cancers into routine clinical practice. Annals of Oncology/ESMO. 2011; 22(12):2616-2624.
26. Janku F, Wheler JJ, Naing A, Falchook GS, Hong DS, Stepanek VM, Fu S, Piha-Paul SA, Lee JJ, Luthra R, Tsimberidou AM and Kurzrock R. PIK3CA mutation H1047R is associated with response to PI3K/AKT/mTOR signaling pathway inhibitors in early-phase clinical trials. Cancer Research. 2013; 73(1):276-284.
27. Travis WD, Brambilla E, Noguchi M, Nicholson AG, Geisinger KR, Yatabe Y, Beer DG, Powell CA, Riely GJ, Van Schil PE, Garg K, Austin JH, Asamura H, Rusch VW, Hirsch FR, Scagliotti G, et al. International association for the study of lung cancer/american thoracic society/european respiratory society international multidisciplinary classification of lung adenocarcinoma. Journal of Thoracic Oncology. 2011; 6(2):244-285.
28. Schildhaus HU, Heukamp LC, Merkelbach-Bruse S, Riesner K, Schmitz K, Binot E, Paggen E, Albus K, Schulte W, Ko YD, Schlesinger A, Ansen S, Engel-Riedel W, Brockmann M, Serke M, Gerigk U, et al. Definition of a fluorescence in-situ hybridization score identifies high-and low-level FGFR1 amplification types in squamous cell lung cancer. Mod Pathol. 2012; 25(11):1473-1480.